New age HCT conditioning regimens: what works and why? Available to Purchase

2.

Bacigalupo

A

,

Ballen

K

,

Rizzo

D

, et al.

Defining the intensity of conditioning regimens: working definitions

.

Biol Blood Marrow Transplant

.

2009

;

15

(

12

):

1628

-

1633

.

3.

Giralt

S

,

Ballen

K

,

Rizzo

D

, et al.

Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the Center for International Blood and Marrow Transplant Research

.

Biol Blood Marrow Transplant

.

2009

;

15

(

3

):

367

-

369

.

4.

Gagelmann

N

,

Kroger

N.

Dose intensity for conditioning in allogeneic hematopoietic cell transplantation: can we recommend “when and for whom” in 2021?

Haematologica

.

2021

;

106

(

7

):

1794

-

1804

.

5.

Spyridonidis

A

,

Labopin

M

,

Savani

BN

, et al.

Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients

.

Bone Marrow Transplant

.

2020

;

55

(

6

):

1114

-

1125

.

6.

Spyridonidis

A

,

Labopin

M

,

Gedde-Dahl

T

, et al.

Validation of the transplant conditioning intensity (TCI) index for allogeneic hematopoietic cell transplantation

.

Bone Marrow Transplant

.

2024

;

59

(

2

):

217

-

223

.

7.

Bolaños-Meade

J

,

Hamadani

M

,

Wu

J

, et al.

Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis

.

N Engl J Med

.

2023

;

388

(

25

):

2338

-

2348

.

8.

Abedin

SM

,

Martens

MJ

,

Bolaños-Meade

J

, et al.

Impact of post-transplant cyclophosphamide-based GVHD prophylaxis in patients 70 years and older: an update from BMT CTN 1703

.

Blood Adv

.

2025

;

9

(

14

):

3495

-

3501

.

9.

Mielcarek

M

,

Furlong

T

,

O'Donnell

PV

, et al.

Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation

.

Blood

.

2016

;

127

(

11

):

1502

-

1508

.

10.

Jurdi

NE

,

Hoover

A

,

O'Leary

D

, et al.

Phase II study of myeloablative 7-8/8-matched allotransplantation with post-transplantation cyclophosphamide, tacrolimus, and mycophenolate mofetil

.

Transplant Cell Ther

.

2023

;

29

(

9

):

576.e571

-

576.e575

.

11.

Eastburg

L

,

Russler-Germain

DA

,

DiPersio

JF

, et al.

Increased early mortality after fludarabine and melphalan conditioning with peripheral blood grafts in haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide

.

Leuk Lymphoma

.

2022

;

63

(

1

):

222

-

226

.

12.

Bornhäuser

M

,

Kienast

J

,

Trenschel

R

, et al.

Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial

.

Lancet Oncol

.

2012

;

13

(

10

):

1035

-

1044

.

13.

Fasslrinner

F

,

Schetelig

J

,

Burchert

A

, et al.

Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: retrospective follow-up of an open-label, randomised phase 3 trial

.

Lancet Haematol

.

2018

;

5

(

4

):

e161

-

e169

.

14.

Kroger

N

,

Iacobelli

S

,

Franke

GN

, et al.

Dose-reduced versus standard conditioning followed by allogeneic stem-cell transplantation for patients with myelodysplastic syndrome: a prospective randomized phase III study of the EBMT (RICMAC trial)

.

J Clin Oncol

.

2017

;

35

(

19

):

2157

-

2164

.

15.

Scott

BL

,

Pasquini

MC

,

Logan

BR

, et al.

Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes

.

J Clin Oncol

.

2017

;

35

(

11

):

1154

-

1161

.

16.

Scott

BL

,

Pasquini

MC

,

Fei

M

, et al.

Myeloablative versus reduced- intensity conditioning for hematopoietic cell transplantation in acute myelogenous leukemia and myelodysplastic syndromes-long-term follow-up of the BMT CTN 0901 Clinical Trial

.

Transplant Cell Ther

.

2021

;

27

(

6

):

483.e1

-

483.e6

.

17.

Hourigan

CS

,

Dillon

LW

,

Gui

G

, et al.

Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease

.

J Clin Oncol

.

2020

;

38

(

12

):

1273

-

1283

.

18.

Paras

G

,

Morsink

LM

,

Othus

M

, et al.

Conditioning intensity and peritransplant flow cytometric MRD dynamics in adult AML

.

Blood

.

2022

;

139

(

11

):

1694

-

1706

.

19.

Ali

N

,

Othus

M

,

Rodríguez-Arbolí

E

, et al.

Measurable residual disease as predictor of post–day +100 relapses after allografting in adult AML

.

Blood Adv

.

2025

;

9

(

3

):

558

-

570

.

20.

Hourigan

CS

,

Dillon

LW

,

Gui

G

, et al.

Pre-MEASURE: a multicenter evaluation of the prognostic significance of measurable residual disease testing prior to allogeneic transplantation for adult patients with AML in first remission

.

J Clin Oncol

.

2022

;

40

(

16

)(suppl):

7006

.

21.

Kolb H-J,

Schmid

C.

The FLAMSA concept—past and future

.

Ann Hematol

.

2020

;

99

(

9

):

1979

-

1988

.

22.

Bours

B

,

Masouridi-Levrat

S

.

Is there (still) a place for sequential conditioning?

Curr Oncol

.

2025

;

32

(

4

):

196

.

23.

Schmid

C

,

Schleuning

M

,

Ledderose

G

,

Tischer

J

,

Kolb

H-J

.

Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome

.

J Clin Oncol

.

2005

;

23

(

24

):

5675

-

5687

.

24.

Schmid

C

,

Schleuning

M

,

Schwerdtfeger

R

, et al.

Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation

.

Blood

.

2006

;

108

(

3

):

1092

-

1099

.

25.

Mohty

M

,

Florent

M

,

Didier

B

, et al.

Sequential regimen of clofarabine, cytosine arabinoside and reduced-intensity conditioned transplantation for primary refractory acute myeloid leukemia

.

Haematologica

.

2016

;

102

(

1

):

184

-

191

.

26.

Duléry

R

,

Ménard

A-L

,

Chantepie

S

, et al.

Sequential conditioning with thiotepa in T cell-replete hematopoietic stem cell transplantation for the treatment of refractory hematologic malignancies: comparison with matched related, haplo-mismatched, and unrelated donors

.

Biol Blood Marrow Transplant

.

2018

;

24

(

5

):

1013

-

1021

.

27.

Le Bourgeois

A

,

Labopin

M

,

Marçais

A

, et al.

Sequential allogeneic hematopoietic stem cell transplantation for active refractory/relapsed myeloid malignancies: results of a reduced-intensity conditioning preceded by clofarabine and cytosine arabinoside, a retrospective study on behalf of the SFGM-TC

.

Ann Hematol

.

2020

;

99

(

8

):

1855

-

1862

.

28.

Heinicke

T

,

Myriam

L

,

Emmanuelle

P

, et al.

Evaluation of six different types of sequential conditioning regimens for allogeneic stem cell transplantation in relapsed/refractory acute myelogenous leukemia—a study of the Acute Leukemia Working Party of the EBMT

.

Leukemia Lymphoma

.

2021

;

62

(

2

):

399

-

409

.

29.

Craddock

C

,

Jackson

A

,

Loke

J

, et al.

Augmented reduced-intensity regimen does not improve postallogeneic transplant outcomes in acute myeloid leukemia

.

J Clin Oncol

.

2021

;

39

(

7

):

768

-

778

.

30.

Rodríguez-Arbolí

E

,

Labopin

M

,

Tischer

J

, et al.

FLAMSA-based reduced-intensity conditioning versus myeloablative conditioning in younger patients with relapsed/refractory acute myeloid leukemia with active disease at the time of allogeneic stem cell transplantation: an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

.

Biol Blood Marrow Transplant

.

2020

;

26

(

11

):

2165

-

2173

.

31.

Schulz

F

,

Jäger

P

,

Tischer

J

, et al.

Smart conditioning with venetoclax- enhanced sequential FLAMSA + RIC in patients with high-risk myeloid malignancies

.

Cancers (Basel)

.

2024

;

16

(

3

):

532

.

32.

Milano

F

,

Sandmaier

BM

,

Percival

M-EM

, et al.

CLAG-M or FLAG-Ida followed immediately by allogeneic hematopoietic cell transplantation for adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasm

.

Blood

.

2024

;

144

(

suppl 1

):

265

.

33.

Clift

RA

,

Buckner

CD

,

Appelbaum

FR

, et al.

Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens

.

Blood

.

1990

;

76

(

9

):

1867

-

1871

.

34.

Pagel

JM

,

Gooley

TA

,

Rajendran

J

, et al.

Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome

.

Blood

.

2009

;

114

(

27

):

5444

-

5453

.

35.

Gyurkocza

B

,

Nath

R

,

Seropian

S

, et al.

Randomized phase III SIERRA trial of ¹³¹I-apamistamab before allogeneic hematopoietic cell transplantation versus conventional care for relapsed/refractory AML

.

J Clin Oncol

.

2025

;

43

(

2

):

201

-

213

.

36.

Vo

P

,

Gooley

TA

,

Rajendran

JG

, et al.

Yttrium-90-labeled anti-CD45 antibody followed by a reduced-intensity hematopoietic cell transplantation for patients with relapsed/refractory leukemia or myelodysplasia

.

Haematologica

.

2020

;

105

(

6

):

1731

-

1737

.

37.

Sandmaier

BM

,

Wilbur

DS

,

Hamlin

DK

, et al.

A phase I trial of first-in-human alpha-emitter astatine-211-labeled anti-CD45 antibody (211At-BC8-B10) in combination with fludarabine and TBI as conditioning for allogeneic hematopoietic cell transplantation (HCT) for patients with refractory/relapsed leukemia or high-risk myelodysplastic syndrome (MDS): preliminary results of dose escalation

.

Transplant Cell Ther

.

2021

;

27

(

3

)(suppl):

S54

.

38.

Rosenthal

J

,

Wong

J

,

Stein

A

, et al.

Phase 1/2 trial of total marrow and lymph node irradiation to augment reduced-intensity transplantation for advanced hematologic malignancies

.

Blood

.

2011

;

117

(

1

):

309

-

315

.

39.

Wong

JY

,

Forman

S

,

Somlo

G

, et al.

Dose escalation of total marrow irradiation with concurrent chemotherapy in patients with advanced acute leukemia undergoing allogeneic hematopoietic cell transplantation

.

Int J Radiat Oncol Biol Phys

.

2013

;

85

(

1

):

148

-

156

.

40.

Patel

P

,

Aydogan

B

,

Koshy

M

, et al.

Combination of linear accelerator-based intensity-modulated total marrow irradiation and myeloablative fludarabine/busulfan: a phase I study

.

Biol Blood Marrow Transplant

.

2014

;

20

(

12

):

2034

-

2041

.

41.

Stein

A

,

Palmer

J

,

Tsai

NC

, et al.

Phase I trial of total marrow and lymphoid irradiation transplantation conditioning in patients with relapsed/refractory acute leukemia

.

Biol Blood Marrow Transplant

.

2017

;

23

(

4

):

618

-

624

.

42.

Hui

S

,

Brunstein

C

,

Takahashi

Y

, et al.

Dose escalation of total marrow irradiation in high-risk patients undergoing allogeneic hematopoietic stem cell transplantation

.

Biol Blood Marrow Transplant

.

2017

;

23

(

7

):

1110

-

1116

.

43.

Ali

N

,

Sharma

AA

,

de Rezende

ACP

, et al.

Targeted marrow irradiation intensification of reduced-intensity fludarabine/busulfan conditioning for allogeneic hematopoietic stem cell transplantation

.

Transplant Cell Ther

.

2022

;

28

(

7

):

370.e1

-

370.e10

.

44.

Al

Malki MM

,

Palmer

J

,

Tsai

NC

, et al.

Total marrow and lymphoid irradiation as conditioning in haploidentical transplant with posttransplant cyclophosphamide

.

Blood Adv

.

2022

;

6

(

14

):

4098

-

4106

.

45.

Jensen

LG

,

Stiller

T

,

Wong

JYC

,

Palmer

J

,

Stein

A

,

Rosenthal

J.

Total marrow lymphoid irradiation/fludarabine/melphalan conditioning for allogeneic hematopoietic cell transplantation

.

Biol Blood Marrow Transplant

.

2018

;

24

(

2

):

301

-

307

.

46.

Qin

T

,

Youssef

EM

,

Jelinek

J

, et al.

Effect of cytarabine and decitabine in combination in human leukemic cell lines

.

Clin Cancer Res

.

2007

;

13

(

14

):

4225

-

4232

.

47.

Goodyear

OC

,

Dennis

M

,

Jilani

NY

, et al.

Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML)

.

Blood

.

2012

;

119

(

14

):

3361

-

3369

.

48.

Cruijsen

M

,

Hobo

W

,

van der Velden

W

, et al.

Addition of 10-day decitabine to fludarabine/total body irradiation conditioning is feasible and induces tumor-associated antigen-specific T cell responses

.

Biol Blood Marrow Transplant

.

2016

;

22

(

6

):

1000

-

1008

.

49.

Cao Y-G,

He

Y

,

Zhang

S-D

, et al.

Conditioning regimen of 5-day decitabine administration for allogeneic stem cell transplantation in patients with myelodysplastic syndrome and myeloproliferative neoplasms

.

Biol Blood and Marrow Transplant

.

2020

;

26

(

2

):

285

-

291

.

50.

Xuan

L

,

Dai

M

,

Jiang

E

, et al.

The effect of granulocyte-colony stimulating factor, decitabine, and busulfan-cyclophosphamide versus busulfan-cyclophosphamide conditioning on relapse in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia evolving from myelodysplastic syndrome undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised, phase 3 trial

.

Lancet Haematol

.

2023

;

10

(

3

):

e178

-

e190

.

51.

Garcia

JS

,

Kim

HT

,

Murdock

HM

, et al.

Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active

.

Blood Adv

.

2021

;

5

(

24

):

5536

-

5545

.

52.

Popat

U

,

Bassett

RL

,

Alousi

AM

, et al.

Myeloablative fractionated busulfan, fludarabine, cladribine, thiotepa and venetoclax (cladillac) conditioning regimen for very high-risk AML/MDS: a phase 2 trial

.

Blood

.

2024

;

144

:

506

.

53.

McSweeney

PA

,

Niederwieser

D

,

Shizuru

JA

, et al.

Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects

.

Blood

.

2001

;

97

(

11

):

3390

-

3400

.

54.

Kornblit

B

,

Maloney

DG

,

Storb

R

, et al.

Fludarabine and 2-Gy TBI is superior to 2 Gy TBI as conditioning for HLA-matched related hematopoietic cell transplantation: a phase III randomized trial

.

Biol Blood Marrow Transplant

.

2013

;

19

(

9

):

1340

-

1347

.

55.

Blaise

D

,

Tabrizi

R

,

Boher

J-M

, et al.

Randomized study of 2 reduced-intensity conditioning strategies for human leukocyte antigen-matched, related allogeneic peripheral blood stem cell transplantation

.

Cancer

.

2013

;

119

(

3

):

602

-

611

.

56.

Heinicke

T

,

Labopin

M

,

Polge

E

, et al.

Fludarabine/busulfan versus fludarabine/total-body-irradiation (2 Gy) as conditioning prior to allogeneic stem cell transplantation in patients (≥60 years) with acute myelogenous leukemia: a study of the acute leukemia working party of the EBMT

.

Bone Marrow Transplant

.

2020

;

55

(

4

):

729

-

739

.

57.

Vo

PT

,

Sandmaier

BM

,

Othus

M

, et al.

Relationship between age, conditioning intensity, and outcome after allografting in adults age ≥60 years with AML

.

Bone Marrow Transplant

.

2025

;

60

(

4

):

482

-

490

.

58.

Walter

RB

,

Sandmaier

BM

,

Othus

M

, et al.

Comparison of reduced intensity and nonmyeloablative conditioning for adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation in first or second remission

.

Bone Marrow Transplant

.

2023

;

58

(

4

):

377

-

385

.

59.

Casper

J

,

Knauf

W

,

Kiefer

T

, et al.

Treosulfan and fludarabine: a new toxicity- reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation

.

Blood

.

2004

;

103

(

2

):

725

-

731

.

60.

Ruutu

T

,

Volin

L

,

Beelen

DW

, et al.

Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial

.

Haematologica

.

2011

;

96

(

9

):

1344

-

1350

.

61.

Casper

J

,

Wolff

D

,

Knauf

W

, et al.

Allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies after dose-escalated treosulfan/fludarabine conditioning

.

J Clin Oncol

.

2010

;

28

(

20

):

3344

-

3351

.

62.

Nemecek

ER

,

Guthrie

KA

,

Sorror

ML

, et al.

Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies

.

Biol Blood Marrow Transplant

.

2011

;

17

(

3

):

341

-

350

.

63.

Beelen

DW

,

Trenschel

R

,

Stelljes

M

, et al.

Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial

.

Lancet Haematol

.

2020

;

7

(

1

):

e28

-

e39

.

64.

Gyurkocza

B

,

Gutman

J

,

Nemecek

ER

, et al.

Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia

.

Biol Blood Marrow Transplant

.

2014

;

20

(

4

):

549

-

555

.

65.

Deeg

HJ

,

Stevens

EA

,

Salit

RB

, et al.

Transplant conditioning with treosulfan/ fludarabine with or without total body irradiation: a randomized phase II trial in patients with myelodysplastic syndrome and acute myeloid leukemia

.

Biol Blood Marrow Transplant

.

2018

;

24

(

5

):

956

-

963

.

66.

Burroughs

LM

,

Nemecek

ER

,

Torgerson

TR

, et al.

Treosulfan-based conditioning and hematopoietic cell transplantation for nonmalignant diseases: a prospective multicenter trial

.

Biol Blood Marrow Transplant

.

2014

;

20

(

12

):

1996

-

2003

.

67.

Sykora

KW

,

Beier

R

,

Schulz

A

, et al.

Treosulfan vs busulfan conditioning for allogeneic BMT in children with nonmalignant disease: a randomized phase 2 trial

.

Bone Marrow Transplant

.

2024

;

59

(

1

):

107

-

116

.

68.

Peccatori

J

,

Forcina

A

,

Clerici

D

, et al.

Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors

.

Leukemia

.

2015

;

29

(

2

):

396

-

405

.

69.

Palchaudhuri

R

,

Saez

B

,

Hoggatt

J

, et al.

Non-genotoxic conditioning for hematopoietic stem cell transplantation using a hematopoietic-cell- specific internalizing immunotoxin

.

Nat Biotechnol

.

2016

;

34

(

7

):

738

-

745

.

70.

Castiello

MC

,

Bosticardo

M

,

Sacchetti

N

, et al.

Efficacy and safety of anti-CD45-saporin as conditioning agent for RAG deficiency

.

J Allergy Clin Immunol

.

2021

;

147

(

1

):

309

-

320

.e306.

71.

Czechowicz

A

,

Palchaudhuri

R

,

Scheck

A

, et al.

Selective hematopoietic stem cell ablation using CD117-antibody-drug-conjugates enables safe and effective transplantation with immunity preservation

.

Nat Commun

.

2019

;

10

(

1

):

617

.

72.

Persaud

SP

,

Yelamali

AR

,

Ritchey

JK

,

DiPersio

JF

.

Fully myeloablative antibody-drug conjugates condition for hematopoietic stem cell transplantation and provide durable antileukemia benefit

.

Blood

.

2022

;

140

(

suppl 1

):

1570

-

1571

.

73.

Arai

Y

,

Choi

U

,

Corsino

CI

, et al.

Myeloid conditioning with c-kit-targeted CAR-T cells enables donor stem cell engraftment

.

Mol Ther

.

2018

;

26

(

5

):

1181

-

1197

.

74.

Raiola

AM

,

Dominietto

A

,

Ghiso

A

, et al.

Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning

.

Biol Blood Marrow Transplant

.

2013

;

19

(

1

):

117

-

122

.

75.

Kanakry

CG

,

O'Donnell

PV

,

Furlong

T

, et al.

Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning

.

J Clin Oncol

.

2014

;

32

(

31

):

3497

-

3505

.

76.

Symons

HJ

,

Zahurak

M

,

Cao

Y

, et al.

Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults

.

Blood Adv

.

2020

;

4

(

16

):

3913

-

3925

.

77.

Luznik

L

,

Pasquini

MC

,

Logan

B

, et al.

Randomized phase III BMT CTN trial of calcineurin inhibitor-free chronic graft-versus-host disease interventions in myeloablative hematopoietic cell transplantation for hematologic malignancies

.

J Clin Oncol

.

2022

;

40

(

4

):

356

-

368

.

78.

Popat

UR

,

Andersson

BS

,

Bassett

R

, et al.

A myeloablative fractionated busulfan conditioning regimen with post-transplant cyclophosphamide in HLA-matched and haploidentical transplantation: results of a phase II study

.

Haematologica

.

2022

;

107

(

10

):

2496

-

2500

.

79.

Fierro-Pineda

JC

,

Tsai

HL

,

Blackford

A

, et al.

Prospective PTCTC trial of myeloablative haplo-BMT with posttransplant cyclophosphamide for pediatric acute leukemias

.

Blood Adv

.

2023

;

7

(

18

):

5639

-

5648

.

80.

Casper

J

,

Holowiecki

J

,

Trenschel

R

, et al.

Allogeneic hematopoietic SCT in patients with AML following treosulfan/fludarabine conditioning

.

Bone Marrow Transplant

.

2012

;

47

(

9

):

1171

-

1177

.